News from the FDA/CDC

FDA approves mAb combo for hepatocellular carcinoma


 

The Food and Drug Administration has approved atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) to treat patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

The approval was supported by results from the IMbrave150 trial (N Engl J Med. 2020;382:1894-1905). This phase 3 trial enrolled 501 patients with hepatocellular carcinoma who were randomized to receive either sorafenib or atezolizumab plus bevacizumab.

The median overall survival was not reached in patients who received atezolizumab plus bevacizumab, but it was 13.2 months in patients who received sorafenib (hazard ratio, 0.58; 95% confidence interval, 0.42-0.79; P = .0006). The median progression-free survival was 6.8 months in patients who received atezolizumab plus bevacizumab and 4.3 months for those who received sorafenib.

The most common adverse events seen in the atezolizumab-bevacizumab arm were hypertension, fatigue, and proteinuria.

The recommended atezolizumab dose is 1,200 mg, followed by 15 mg/kg bevacizumab on the same day every 3 weeks.

The FDA collaborated with regulatory agencies from Canada, Australia, and Singapore on the review of the atezolizumab application, as part of Project Orbis. The FDA approved the application ahead of schedule. It is still under review for the other agencies.

Recommended Reading

Three months of COVID-19 may mean 80,000 missed cancer diagnoses
Journal of Clinical Outcomes Management
Altering gut microbiome may reduce tumor-promoting effects of smoking
Journal of Clinical Outcomes Management
COVID-19 death rate was twice as high in cancer patients in NYC study
Journal of Clinical Outcomes Management
ASCO goes ahead online, as conference center is used as hospital
Journal of Clinical Outcomes Management
Blood test detects colon cancer in single-center study
Journal of Clinical Outcomes Management
Video coaching may relieve anxiety and distress for long-distance cancer caregivers
Journal of Clinical Outcomes Management
‘Momentous’ data for first-line combo in liver cancer
Journal of Clinical Outcomes Management
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Journal of Clinical Outcomes Management
Active cancer increases death risk in patients with COVID-19
Journal of Clinical Outcomes Management
Upfront pembrolizumab doubles PFS in MSI-H/dMMR metastatic colorectal cancer
Journal of Clinical Outcomes Management